Alternate Name(s):
BUSCOPAN, BUTYLSCOPOLAMINE
Classification:
Anticholinergic
Original Date:
February 2016
Indications:
- To produce smooth muscle relaxation prior to radiological procedures where spasm may be a problem
- Hyoscine butylbromide is a semisynthetic derivative of scopolamine but the doses are NOT equivalent (for hyoscine hydrobromide see SCOPOLAMINE monograph)
Reconstitution and Stability:
- Available as 20 mg/mL clear solution
- Store at room temperature and protect from light
- Stable 8 hours when mixed with D5W, D10W, 0.9% NaCl, ringer's solution, ringer's lactate
Compatibility:
- Solutions Compatible: D5W, D10W, ringer's solution, ringer's lactate
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | YES |
| IM | YES |
| IV Direct | YES Usual dilution: undiluted Infusion time: over at least 1 minute |
|
IV Intermittent Infusion |
YES Usual dilution: dilute in at least 5 mL of IV fluid Infusion time: 15 minutes |
| IV Continuous Infusion | NO |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
Pediatric:
- MR Enterography
- less than or equal to 50 kg - 0.3 mg/kg/dose IV
- greater than 50 kg - 20 mg/dose IV
Potential hazards of parenteral administration:
- Tachycardia or hypotension
- Dry mouth, blurry vision, constipation, urinary retention
- Disorientation, delirium, confusion, psychosis, drowsiness
- Depressed respiration
Notes:
- Monitor heart rate
- Infants and children are more susceptible than adults to the adverse effects of anticholinergics
- Contraindicated in acute glaucoma, mechanical stenosis of the GI or urinary tract, tachycardia or cardiac arrhythmias
- May enhance anticholinergic side effects of antihistamines
- Use with caution in reflux esophagitis and cardiac disease
- DO NOT confuse with hyoscine hydrobromide